What is the reported valuation range for Nuvalent in GSK's potential acquisition, and what is Nuvalent's current market value?

According to the Financial Times report cited in the news, GSK is in talks to acquire Nuvalent for a value 'between $9 billion and $10 billion'. The article also states that Nuvalent has a current market value of 'nearly $7 billion', as per LSEG data.

What is Nuvalent's therapeutic focus, and what stage of development are its drug candidates in?

Nuvalent is described as a 'clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer', as stated on its website and quoted directly in the news body.

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

Jun 8, 2026

UK pharmaceutical group GSK is in talks to acquire cancer biotech Nuvalent for over $9 billion, aiming to expand its product pipeline. The potential deal reflects a broader biopharma M&A frenzy projected to exceed $250 billion by 2026.

reuters

2026-06-08

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

2026-06-08

GSK Boosts Lung Cancer Portfolio with $10.6 Billion Nuvalent Takeover

2026-06-09

GSK to buy cancer drug developer Nuvalent for $10.6 billion

2026-06-09

US Stock Futures Rise as Chip Stocks Extend Gains; Oil Prices Drop on Ceasefire Hopes

2026-06-09

GSK Makes Biggest Ever Acquisition with $10.6bn for US Cancer Drug Firm